An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures

Diabetes

Volumn 52, Issue 9, 2003, Pages 2315-2320

  Bennett, Robert G ^a,b   Hamel, Frederick G ^a,b   Duckworth, William C ^c,d,e  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^c CARL T HAYDEN VA MEDICAL CENTER   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLOID; BACITRACIN; CONGO RED; ENZYME INHIBITOR; INSULINASE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; FLUORESCENCE; INSULIN DEGRADATION; INSULINOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; RAT;

AMYLOID; ANIMALS; BACITRACIN; DRUG SYNERGISM; ENZYME INHIBITORS; HYPOGLYCEMIC AGENTS; INSULIN; INSULINOMA; INSULYSIN; IODINE RADIOISOTOPES; PANCREATIC NEOPLASMS; RATS; TUMOR CELLS, CULTURED;

EID: 0042822110     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.9.2315     Document Type: Article

References (39)

1. Kahn SE, Andrikopoulos S, Verchere CB: Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48:241-253, 1999
2. Kahn SE, D'Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, Taborsky GJ Jr, Porte D Jr: Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes 39:634-638, 1990
3. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC: The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48:491-498, 1999
4. Janson J, Soeller WC, Roche PC, Nelson RT, Torchia AJ, Kreutter DK, Butler PC: Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci U S A 93:7283-7288, 1996
5. Verchere CB, D'Alessio DA, Wang S, Andrikopoulos S, Kahn SE: Transgenic overproduction of islet amyloid polypeptide (amylin) is not sufficient for islet amyloid formation. Horm Metab Res 29:311-316, 1997
6. Hoppener JW, Verbeek JS, de Koning EJ, Oosterwijk C, van Hulst KL, Visser-Vernooy HJ, Hofhuis FM, van Gaalen S, Berends MJ, Hackeng WH, et al: Chronic overproduction of islet amyloid polypeptide/amylin in transgenic mice: lysosomal localization of human islet amyloid polypeptide and lack of marked hyperglycaemia or hyperinsulinaemia. Diabetologia 36:1258-1265, 1993
7. Fox N, Schrementi J, Nishi M, Ohagi S, Chan SJ, Heisserman JA, Westermark GT, Leckstrom A, Westermark P, Steiner DF: Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes mellitus (NIDDM). FEBS Lett 323:40-44, 1993
8. Couce M, Kane LA, O'Brien TD, Charlesworth J, Soeller W, McNeish J, Kreutter D, Roche P, Butler PC: Treatment with growth hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and beta-cell dysfunction. Diabetes 45:1094-1101, 1996
9. Verchere CB, D'Alessio DA, Palmiter RD, Weir GC, Bonner-Weir S, Baskin DG, Kahn SE: Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci U S A 93:3492-3496, 1996
10. Hoppener JW, Oosterwijk C, Nieuwenhuis MG, Posthuma G, Thijssen JH, Vroom TM, Ahren B, Lips CJ: Extensive islet amyloid formation is induced by development of type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 42:427-434, 1999
11. Duckworth WC, Bennett RG, Hamel FG: Insulin degradation: progress and potential. Endocr Rev 19:608-624, 1998
12. Kurochkin IV: Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem Sci 26:421-425, 2001
13. Bennett RG, Duckworth WC, Hamel FG: Degradation of amylin by insulin-degrading enzyme. J Biol Chem 275:36621-36625, 2000
14. VekreUis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ: Neurous regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci 20:1657-1665, 2000
15. Shii K, Roth RA: Inhibition of insulin degradation by hepatoma cells after microinjection of monoclonal antibodies to a specific cytosolic protease. Proc Natl Acad Sci U S A 83:4147-4151, 1986
16. Bhathena SJ, Oie HK, Gazdar AF, Voyles NR, Wilkins SD, Recant L: Insulin, glucagon, and somatostafin receptors on cultured cells and clones from rat islet cell tumor. Diabetes 31:521-531, 1982
17. Peavy DE, Edmondson JW, Duckworth WC: Selective effects of inhibitors of hormone processing on insulin action in isolated hepatocytes. Endocrinology 114:753-760, 1984
18. Churukian CJ: Improved Puchtler's Congo red method for demonstrating amyloid. J Histotechnol 23:139-141, 2000
19. Hansen MB, Nielsen SE, Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119:203-210, 1989
20. Westermark P, Li ZC, Westermark GT, Leckstrom A, Steiner DF: Effects of beta cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett 379:203-206, 1996
21. Puchtler H, Sweat F, Levine M: On the binding of Congo red by amyloid. J Histochem Cytochem 10:355-364, 1962
22. Howard CF: Longitudinal studies on the development of diabetes in individual Macaca nigra. Diabetologia 29:301-306, 1986
23. Kahn SE, Verchere CB, Andrikopoulos S, Asberry PJ, Leonetti DL, Wahl PW, Boyko EJ, Schwartz RS, Newell-Morris L, Nimoto WY: Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 47:640-645, 1998
24. Westermark P: Amyloid and polypeptide hormones. What is their relationship? Amyloid 1:47-60, 1994
25. D'Alessio DA, Verchere CB, Kahn SE, Hoagland V, Baskin DG, Palmiter RD, Ensinck JW: Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. Diabetes 43:1457-1461, 1994
26. Becker AB, Roth RA: Insulysin and pitrilysin: insulin-degrading enzymes of mammals and bacteria. Meth Enzymol 248:693-703, 1995
27. Sipe JD: Amyloidosis. Annu Rev Biochem 61:947-975, 1992
28. Kurochkin IV: Amyloidogenic determinant as a substrate recognition motif of insulin-degrading enzyme. FEBS Lett 427:153-156, 1998
29. Goto S, Kurochkin IV: Alzheimer's's β-amyloid peptide interacts with and is degraded by insulin degrading enzyme. FEBS Lett 345:33-37, 1994
30. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ: Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 273:32730-32738, 1998
31. Wiltshire S, Hattersley AT, Hitman GA, Walker M, Levy JC, Sampson M, O'Rahilly S, Frayling TM, Bell JI, Lathrop GM, Bennett A, Dhillon R, Fletcher C, Groves CJ, Jones E, Prestwich P, Simecek N, Rao PV, Wishart M, Bottazzo GF, Foxon R, Howell S, Smedley D, Cardon LR, Menzel S, McCarthy MI: A genomewide scan for loci predisposing to type 2 diabetes in a U.K. population (the Diabetes UK Warren 2 Repository): analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q. Am J Hum Genet 69:553-569, 2001
32. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, Yhu S, McInnis MG, Go RC, Vekrellis K, Selkoe DJ, Saunders AJ, Tanzi RE: Evidence for genetic linkage of Alzheimer's's disease to chromosome 10q. Science 290:2302-2303, 2000
33. Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D, Shears S, Booth J, DeVrieze FW, Crook R, Hamshere M, Abraham R, Tunstall N, Rice F, Carty S, Lillystone S, Kehoe P, Rudrasingham V, Jones L, Lovestone S, Perez-Tur J, Williams J, Owen MJ, Hardy J, Goate AM: Susceptibility locus for Alzheimer's's disease on chromosome 10. Science 290:2304-2305, 2000
34. Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Baker M, Adamson J, Ronald J, Blangero J, Hutton M, Younkin SG: Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's's disease pedigrees. Science 290:2303-2304, 2000
35. Fakhrai-Rad H, Nikoshkov A, Kamel A, Fernstrom M, Zierath JR, Norgren S, Luthman H, Galli J: Insulin-degrading enzyme identified as a candidate diabetes susceptibility gene in GK rats. Hum Mol Genet 9:2149-2158, 2000
36. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S: Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100:4162-4167, 2003
37. Bhathena SJ, Timmers KI, Oie HK, Voyles NR, Recant L: Cytosolic insulin-degrading activity in islet-derived tumor cell lines and in normal rat islets. Diabetes 34:121-128, 1985
38. Oehler G, Bleyl H, Matthes KJ: Hyperinsulinemia in hepatic steatosis. Int J Obe Relat Metab Disord 6 (Suppl. 1):137-144, 1982
39. Hamel FG, Upward JL, Bennett RG: In vitro inhibition of insulin-degrading enzyme by long chain fatty acids and their coenzyme A thioesters. Endocrinology 144:2404-2408, 2003